Highlights

  • FY26 product sales growth of 42% year-on-year, with first sales recorded in India and Indonesia — markets with a combined 560 million women of screening age.
  • Three proposals submitted to UNITAID covering 14 high-burden countries across Africa, Asia-Pacific, and Latin America, with potential Revenue as consortium lead of up to US$18.4 million.
  • Gross Margin improved to 31.5% (from 30.1%), with further improvement expected in FY27 as geographic revenue Diversification continues.

 

TruScreen Group Limited (ASX:TRU), the New Zealand-based medical device company with a proprietary AI-enabled cervical cancer screening technology, released preliminary FY26 financial results on 29 May 2026 showing product sales growth of 42% year-on-year — the fastest rate of commercial expansion the company has reported in recent years — driven by new market entries in India and Indonesia and continued growth across its existing geographic base.

TRU shares were trading 5.88% lower at AUD 0.016 per share at the time of writing on 29 May 2026.

Financial Performance: Growth Alongside Investment

The 42% growth in product sales occurred against a backdrop of deliberate geographic expansion investment. Gross margin improved modestly to 31.5% from 30.1% in FY25, reflecting the improving revenue scale partially offset by the costs associated with entering new markets with different logistics and distribution profiles. Management expects further margin improvement in FY27 as revenues broaden across a larger country footprint.

Total overhead expenses were NZ$3.4 million, up from NZ$3.1 million in FY25, reflecting additional Marketing and distributor support costs. The net loss for the year was NZ$2.25 million, essentially flat against the NZ$2.24 million loss in FY25 — meaning that the incremental margin from 42% sales growth was almost entirely absorbed by the investment in geographic expansion. For a company at TruScreen's stage, this is a deliberate rather than accidental trade-off.

The company raised approximately NZ$4 million during FY26 through the issue of approximately 190.7 million shares, funding its expansion initiatives and international engagement program.

New Markets: India and Indonesia as Growth Vectors

The commercial and strategic significance of TruScreen's India and Indonesia entries cannot be overstated in the context of the company's addressable market. India has approximately 468 million women of screening age (CIA World Factbook, ages 15–64), while Indonesia has approximately 96 million. Together, these two markets represent a larger addressable screening population than Europe.

India presents particular institutional complexity, given the diversity of healthcare delivery models across state health systems and private providers. TruScreen appointed Renovate Biologicals Pvt Ltd as its Indian distributor during FY26 — a critical first step in establishing a commercial presence in a market where local distribution expertise is essential.

Indonesia's relevance is amplified by the existence of a government-funded mass screening program, which creates a pathway for TruScreen to participate in publicly financed cervical cancer elimination initiatives — the type of large-Volume, recurring engagement that can materially change the company's revenue trajectory.

UNITAID Proposals: The Largest Single Opportunity

TruScreen submitted three proposals to UNITAID's Global Cervical Cancer Elimination Call to Action, covering 14 high-burden countries in Africa, Asia-Pacific, and Latin America. The addressable screening market referenced across these 14 countries is stated as one billion women, with potential revenue as consortium lead of up to US$18.4 million.

UNITAID is a global health initiative housed within the World Health Organization, funded primarily by levies on airline tickets in member countries, with a mandate to accelerate access to health innovations in low- and middle-income countries. A successful UNITAID grant would provide TruScreen with funded access to markets and patient populations that would otherwise require years of independent commercial development to penetrate.

TruScreen's point-of-care device — portable, battery-operable, AI-enabled, and requiring no laboratory infrastructure or pathologist review — is specifically engineered for settings where conventional Pap smear or colposcopy-based screening is infeasible. This design positioning makes it particularly well-suited to UNITAID's mandate in high-burden, resource-constrained settings.

China and Geographic Concentration Risk

China remained TruScreen's largest market in FY26, accounting for 61.3% of total sales. While Chinese consumable volumes met expectations despite challenging macroeconomic conditions, this concentration level represents a meaningful risk Factor — any disruption to China operations or market access could disproportionately affect group revenues.

The company's geographic diversification strategy — evident in the India, Indonesia, South Africa, Uzbekistan, and Central Asian entries — is directly addressing this concentration. As revenues from newer markets grow, China's share of total revenue should decline, improving the resilience of the overall portfolio.

Conclusion

TruScreen's FY26 results reflect a company in an active market development phase, prioritising geographic reach over near-term profitability. The 42% sales growth, combined with entries into India and Indonesia, three UNITAID proposals, and an improving distribution network, demonstrates genuine commercial momentum. The return of CEO Martin Dillon from 1 June 2026 adds Leadership continuity to a Business approaching what management describes as a transformational growth phase.